---
schema_version: "secwatch.filing_event.v1"
accession: "0001658247-25-000018"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:45:43.341006+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Crinetics Q3 net loss $130.1M; PALSONIFY launched for acromegaly after FDA approval

## Summary
- PALSONIFY (paltusotine) approved by FDA Sept 25 for first-line acromegaly; ~95% of top-priority HCP targets called, ~50% of filled prescriptions reimbursed.
- Q3 2025 net loss $130.1M vs $76.8M YoY; R&D $90.5M (+46%), SG&A $52.3M (+102%) driven by launch and pipeline.
- Cash, equivalents and investments $1.1B; cash burn guidance $340-370M for 2025; runway into 2029.
- Phase 3 CAREFNDR (carcinoid syndrome) and Phase 3 CALM-CAH (CAH) expected to start Q4 2025; Phase 1/2 CRN09682 also Q4.
- TSHR antagonist program shifted to alternative candidate; SST3 IND postponed after preclinical data.

## SEC filing metadata
- accession: 0001658247-25-000018
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000165824725000018/0001658247-25-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000165824725000018/crnx-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001658247-25-000018
- JSON: https://secwatch.observer/filing/0001658247-25-000018.json
- Plain text: https://secwatch.observer/filing/0001658247-25-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.